Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

UNKNOWN × Interventional × aumolertinib × Clear all

Phase

Status

Enrolling by invitation 1

Sponsor Class

OTHER 28 INDUSTRY 12 UNKNOWN 1 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 18 Capecitabine 16 S 1 (combination) 14 Cisplatin 13 Oxaliplatin 11 Radiotherapy, Intensity-Modulated 8 Carboplatin 8 apatinib 7 Radiotherapy 7 Irinotecan 7 Epirubicin 7 pyrotinib 6 anlotinib 6 Docetaxel 6 sintilimab 5 camrelizumab 5 Etoposide 5 Drug Therapy 5 Bevacizumab 5 Albumin-Bound Paclitaxel 5 titanium silicide 4 nedaplatin 4 Vinorelbine 4 Trastuzumab 4 Gemcitabine 4 Cyclophosphamide 4 130-nm albumin-bound paclitaxel 4 toripalimab 3 nimotuzumab 3 Temozolomide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04762459 2022-02-24

APEX

ChineseAMS

Phase 3 Enrolling by invitation

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡